<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251378</url>
  </required_header>
  <id_info>
    <org_study_id>2015-013-00US1</org_study_id>
    <nct_id>NCT03251378</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer</brief_title>
  <official_title>A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, dose escalation and expansion clinical trial to evaluate the safety,&#xD;
      tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic&#xD;
      colorectal cancer and metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, dose escalation and expansion clinical trial to evaluate the&#xD;
      safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The&#xD;
      study will consist of two phases:&#xD;
&#xD;
        -  A dose escalation phase - A 3+3 design will be used for this portion of the study.&#xD;
&#xD;
        -  A dose expansion phase - Five cohorts will be evaluated in Dose Expansion. Cohort A will&#xD;
           evaluate the MTD/RP2D in patients with advanced solid tumors. Cohort B and Cohort C will&#xD;
           evaluate the MTD/RP2D in metastatic colorectal cancer patients. Cohort D and Cohort E&#xD;
           will evaluate the MTD/RP2D in metastatic breast cancer patients.&#xD;
&#xD;
      Study will be conducted in up to 9 sites in the US.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of DLT in each cohort</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>The primary endpoint of the dose escalation phase is the incidence of DLT in each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS) at 12 weeks</measure>
    <time_frame>From first dose of study drug through 12 weeks of treatment</time_frame>
    <description>Primary outcome expansion: progression free survival (PFS) at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration calculated with blood samples</measure>
    <time_frame>within 30 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration calculated with blood samples</measure>
    <time_frame>within 30 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>every 4 weeks or every 8 weeks depending on cohort, through study completion, an average of 6 months</time_frame>
    <description>the proportion of of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Colon Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Hormone Receptor Positive Breast Carcinoma</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>3 mg Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fruquintinib Expansion Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Colorectal Cancer Expansion Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Colorectal Cancer Expansion Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer Expansion Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer Expansion Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib (HMPL-013)</intervention_name>
    <description>Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.</description>
    <arm_group_label>3 mg Dose Escalation</arm_group_label>
    <arm_group_label>5 mg Dose Escalation</arm_group_label>
    <arm_group_label>Fruquintinib Expansion Cohort A</arm_group_label>
    <arm_group_label>Metastatic Breast Cancer Expansion Cohort D</arm_group_label>
    <arm_group_label>Metastatic Breast Cancer Expansion Cohort E</arm_group_label>
    <arm_group_label>Metastatic Colorectal Cancer Expansion Cohort B</arm_group_label>
    <arm_group_label>Metastatic Colorectal Cancer Expansion Cohort C</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Fully understand the study and voluntarily sign the ICF;&#xD;
&#xD;
          -  ≥18years of age;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
        Dose Escalation Phase:&#xD;
&#xD;
        • Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
        malignancy of any type (except squamous NSCLC) that has progressed on approved systemic&#xD;
        therapy, and for whom no effective therapy or standard of care exists. This cohort is&#xD;
        closed to enrollment.&#xD;
&#xD;
        Dose Expansion Phase:&#xD;
&#xD;
          -  Cohort A: Histologically or cytologically documented, locally advanced or metastatic&#xD;
             solid malignancy of any type (except squamous NSCLC), that has progressed on approved&#xD;
             systemic therapy, and for whom no effective therapy or standard of care exists. This&#xD;
             cohort is closed to enrollment.&#xD;
&#xD;
          -  Cohort B: Histologically or cytologically documented mCRC in patients that have&#xD;
             progressed on, or had intolerable toxicity with at least 1 FDA-approved third-line&#xD;
             systemic therapy (trifluridine/tipiracil or regorafenib). Patients must also have been&#xD;
             previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based&#xD;
             chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy for patients&#xD;
             who had RAS wild-type tumors. This cohort is currently enrolling.&#xD;
&#xD;
          -  Cohort C: Histologically or cytologically documented adenocarcinoma of the colon or&#xD;
             rectum. Patients must have progressed on, or had intolerable toxicity to, at least 2&#xD;
             prior regimens of standard chemotherapy, but must not have received prior TAS-102 or&#xD;
             regorafenib. Prior therapy could have included adjuvant chemotherapy if a tumor had&#xD;
             recurred within 6 months after the last administration of treatment. Patients must&#xD;
             have been previously treated with fluoropyrimidine-, oxaliplatin-, and&#xD;
             irinotecan-based chemotherapy, an anti-VEGF biological therapy and, if RAS wild-type,&#xD;
             an anti-EGFR therapy&#xD;
&#xD;
          -  Cohort D only: Histologically- or cytologically-confirmed Her2-negative, hormone&#xD;
             receptor positive (ER+ and/or PR+) breast cancer&#xD;
&#xD;
          -  Cohort E only: Histologically- or cytologically- confirmed triple negative breast&#xD;
             cancer&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study, if any of the following criteria is met:&#xD;
&#xD;
          -  Severe anemia, neutropenia, thrombocytopenia&#xD;
&#xD;
          -  Moderate to severe renal or hepatic impairment&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or&#xD;
             ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history&#xD;
             of perforation of fistulas; or any other condition that could possibly result in&#xD;
             gastrointestinal tract hemorrhage or perforation within 6 months prior to screening;&#xD;
&#xD;
          -  History of a thromboembolic event (including deep vein thrombosis [DVT], pulmonary&#xD;
             embolism, stroke and/or transient ischemic attack) within 6 months prior to screening;&#xD;
&#xD;
          -  Patients with squamous NSCLC;&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, including but not limited to acute&#xD;
             myocardial infarction or coronary artery bypass surgery within 6 months prior to&#xD;
             enrollment, severe or unstable angina pectoris, New York Heart Association Class&#xD;
             III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left&#xD;
             ventricular ejection fraction (LVEF) &lt;50%;&#xD;
&#xD;
          -  Patients who have ever received a VEGFR inhibitor, except for patients with mCRC&#xD;
             enrolled in the dose expansion phase;&#xD;
&#xD;
          -  Systemic anti-neoplastic therapies or any investigational therapy within 4 weeks prior&#xD;
             to the first dose of study drug, including chemotherapy, radical radiotherapy,&#xD;
             hormonotherapy, biotherapy and immunotherapy;&#xD;
&#xD;
          -  Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5&#xD;
             half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;&#xD;
&#xD;
          -  Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the&#xD;
             initiation of study drug;&#xD;
&#xD;
          -  Brachytherapy (ie, implantation of radioactive seeds) within 60 days prior to the&#xD;
             first dose of study drug;&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Known clinically significant history of liver disease, including cirrhosis, current&#xD;
             alcohol abuse or active viral hepatitis. For patients with evidence of chronic&#xD;
             hepatitis B (HBV), the HBV viral load must be undetectable on suppressive therapy, if&#xD;
             indicated. Patients with a history of hepatitis C virus (HCV) infection must have been&#xD;
             treated and cured. For patients with HCV who are currently on treatment, they are&#xD;
             eligible if they have an undetectable HCV viral load;&#xD;
&#xD;
          -  Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or&#xD;
             inferior vena cava.;&#xD;
&#xD;
          -  Women who are pregnant or lactating;&#xD;
&#xD;
          -  Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of stable disease for 14 days or&#xD;
             longer; patients requiring steroids within 4 weeks prior to start of study treatment&#xD;
             will be excluded;&#xD;
&#xD;
          -  No other malignancy, except for non-melanoma skin cancer, during the 5 years prior to&#xD;
             screening;&#xD;
&#xD;
          -  Inability to take medication orally, dysphagia or an active gastric ulcer resulting&#xD;
             from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or&#xD;
             any other condition that investigators believe may affect absorption of the&#xD;
             investigational product;&#xD;
&#xD;
          -  Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory&#xD;
             result, or any other condition that investigators suspect may prohibit use of the&#xD;
             investigational product, affect interpretation of study results, or put the patient at&#xD;
             undue risk of harm based on the investigator's assessment;&#xD;
&#xD;
          -  Known hypersensitivity to fruquintinib or any of its excipients.&#xD;
&#xD;
          -  For Cohort C only: patients who have been previously treated with TAS-102 or&#xD;
             regorafenib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Schelman</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma International Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Fernandez</last_name>
    <phone>+1-973-567-3891</phone>
    <email>albertof@hutch-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keneikia Morgan</last_name>
    <email>keneikiam@hutch-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanios Bekaii-Saab</last_name>
      <phone>480-342-4800</phone>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Care Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kosmo</last_name>
      <phone>760-747-8935</phone>
      <phone_ext>507</phone_ext>
    </contact>
    <investigator>
      <last_name>Michael Kosmo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Anderson</last_name>
      <phone>707-521-3896</phone>
    </contact>
    <investigator>
      <last_name>Ian Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Leal</last_name>
      <phone>303-724-3842</phone>
    </contact>
    <investigator>
      <last_name>Alexis Leal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hem-Onc Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Yeckes-Rodin</last_name>
      <phone>772-335-5666</phone>
    </contact>
    <investigator>
      <last_name>Heather Yeckes-Rodin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joleen Hubbard</last_name>
      <phone>507-255-2912</phone>
    </contact>
    <investigator>
      <last_name>Joleen Hubbard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haeseong Park</last_name>
      <phone>314-362-5740</phone>
    </contact>
    <investigator>
      <last_name>Haeseong Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Eng</last_name>
      <phone>615-936-8422</phone>
    </contact>
    <investigator>
      <last_name>Cathy Eng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Dasari</last_name>
      <phone>713-792-6161</phone>
    </contact>
    <investigator>
      <last_name>Arvind Dasari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>colorectal</keyword>
  <keyword>breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

